NASDAQ:GOSS Gossamer Bio Q4 2024 Earnings Report $0.15 -0.02 (-9.45%) Closing price 04:00 PM EasternExtended Trading$0.16 +0.00 (+1.17%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Gossamer Bio EPS ResultsActual EPS-$0.15Consensus EPS -$0.15Beat/MissMet ExpectationsOne Year Ago EPSN/AGossamer Bio Revenue ResultsActual Revenue$9.38 millionExpected Revenue$7.02 millionBeat/MissBeat by +$2.36 millionYoY Revenue GrowthN/AGossamer Bio Announcement DetailsQuarterQ4 2024Date3/18/2025TimeBefore Market OpensConference Call DateThursday, March 13, 2025Conference Call Time10:30AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual Report(10-K) Gossamer Bio Earnings HeadlinesGossamer Bio: Q2 Earnings SnapshotAugust 13 at 6:12 PM | sfgate.comGossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13 at 6:12 PM | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.August 14 at 1:00 AM | Weiss Ratings (Ad)Gossamer Bio Inc.August 13 at 7:27 AM | marketwatch.comKuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law FirmAugust 10, 2026 | prnewswire.comAnalysts Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $3.20August 6, 2026 | americanbankingnews.comSee More Gossamer Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email. Email Address About Gossamer BioGossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need. The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies. In addition to these clinical-stage assets, Gossamer Bio maintains several earlier-stage programs targeting pathways such as integrin and TGF-β signaling. The company’s R&D efforts are supported by a combination of in-house research capabilities and external collaborations with academic centers and contract research organizations. Gossamer Bio completed its initial public offering in July 2019 and has since advanced multiple clinical trials across North America and selected international sites. The company is led by President and Chief Executive Officer Thomas A. Whiting, a veteran of the biopharmaceutical industry with over 25 years of drug development experience. Under his leadership, Gossamer Bio continues to build a multidisciplinary management team focused on accelerating the translation of scientific insights into therapeutic candidates.View Gossamer Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
